title: Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
abstract: Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis. The drug's mechanism of action is derived from extensive immunologic and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, respectively, as key mediators of psoriasis. Ustekinumab is a completely human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23. The drug has demonstrated efficacy, short-term safety, and convenience of use in the treatment of plaque psoriasis and psoriatic arthritis. Though long-term safety concerns remain, ustekinumab adds to the current treatment armamentarium and holds promise to improve quality of life. This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clinical trials.
authors.affiliation: Department of Dermatology, School of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. daniel.zaghi@hsc.utah.edu
authors.forename: Daniel
authors.initials: D
authors.lastname: Zaghi
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: Kristina
authors.initials: K
authors.lastname: Callis Duffin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D011565:Psoriasis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab